Handle region peptide, rat |
| Catalog No.GC30633 |
Handle region peptide, rat is a prorenin receptor antagonist, suppresses the progression of diabetic nephropathy and has anti-inflammatory in the eye.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 749227-53-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Handle region peptide, rat is a prorenin receptor antagonist, suppresses the progression of diabetic nephropathy and has anti-inflammatory in the eye.
Handle region peptide, rat is a (pro)renin receptor antagonist. Handle region peptide, rat (1 μM) reduces the ratio of active to total ERK1/2. Handle region peptide, rat (0.1-1 μM) reduces TGF-β1 mRNA level, and inhibits the mesangial cells proliferation in a dose-dependent manner. Handle region peptide, rat (0.01-1 μM) increases the MMP-2 activity[1].
Handle region peptide, rat (0.1 mg/kg) suppresses leukocyte adhesion in the endotoxin-induced uveitis (EIU) retina, and decreases the leukocyte counts in rats. Handle region peptide, rat (0.1 mg/kg) lowers the protein concentration in EIU rats induced by LPS, and reduces the mRNA expression and the protein levels of inflammatory mediators such as ICAM-1, CCL2/MCP-1, and IL-6 in rats[2].
[1]. He M, et al. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur J Pharmacol. 2009 Mar 15;606(1-3):155-61. [2]. Satofuka S, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2686-92.
Cell experiment: | The immortalized rat glomerular mesangial cells are incubated at 37°C in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% bovine calf serum (BCS) in a humidified atmosphere of 95% air plus 5% CO2. When the cell reaches about 80% confluence, they are made quiescent by decreasing BCS to 0.5% for 24 to 48 h. To detect the effect of Handle region peptide on p44/42 MAP kinase, the cells are further cultured in serum-deprived medium for 24 h before 1 µM Handle region peptide is added in. The cells are harvested at 0, 1, 5, 10, 60, 120 min time points after Handle region peptide application. Protein isolated from cell lyses is used for subsequent Western blotting analysis[1]. |
Animal experiment: | Rats[2]Long-Evans rats (5-7 weeks old) are treated with 0.1-mL intraperitoneal injections of vehicle (PBS) or Handle region peptide (0.1 or 0.01 mg/kg body weight) the day before and immediately after the injection of LPS. The effects of Handle region peptide treatment on ocular inflammation are evaluated 24 hours after LPS injection[2]. |
References: [1]. He M, et al. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur J Pharmacol. 2009 Mar 15;606(1-3):155-61. | |
| Cas No. | 749227-53-0 | SDF | |
| Canonical SMILES | Arg-Ile-Leu-Leu-Lys-Lys-Met-Pro-Ser-Val | ||
| Formula | C54H101N15O12 S | M.Wt | 1184.54 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8442 mL | 4.221 mL | 8.4421 mL |
| 5 mM | 0.1688 mL | 0.8442 mL | 1.6884 mL |
| 10 mM | 0.0844 mL | 0.4221 mL | 0.8442 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *